ATE441430T1 - Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich) - Google Patents
Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich)Info
- Publication number
- ATE441430T1 ATE441430T1 AT05756838T AT05756838T ATE441430T1 AT E441430 T1 ATE441430 T1 AT E441430T1 AT 05756838 T AT05756838 T AT 05756838T AT 05756838 T AT05756838 T AT 05756838T AT E441430 T1 ATE441430 T1 AT E441430T1
- Authority
- AT
- Austria
- Prior art keywords
- hemorrhagia
- factor viia
- preventing
- intracerebral
- attenuation
- Prior art date
Links
- 229940012414 factor viia Drugs 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 108010054265 Factor VIIa Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400972 | 2004-06-21 | ||
| DKPA200400981 | 2004-06-23 | ||
| PCT/EP2005/052890 WO2005123118A1 (en) | 2004-06-21 | 2005-06-21 | Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE441430T1 true ATE441430T1 (de) | 2009-09-15 |
Family
ID=35058275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05756838T ATE441430T1 (de) | 2004-06-21 | 2005-06-21 | Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich) |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060019894A1 (de) |
| EP (1) | EP1761274B1 (de) |
| JP (2) | JP5523671B2 (de) |
| KR (1) | KR20070027709A (de) |
| AT (1) | ATE441430T1 (de) |
| AU (1) | AU2005253749A1 (de) |
| BR (1) | BRPI0512316A (de) |
| CA (1) | CA2570330A1 (de) |
| DE (1) | DE602005016406D1 (de) |
| ES (1) | ES2331653T3 (de) |
| MX (1) | MXPA06015045A (de) |
| RU (1) | RU2006144397A (de) |
| WO (1) | WO2005123118A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156481A1 (en) * | 2005-07-15 | 2009-06-18 | Novo Nordisk Healthcare A/G | Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy |
| JP2011509978A (ja) * | 2008-01-18 | 2011-03-31 | ノボ ノルディスク ヘルス ケア アーゲー | 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用 |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| EP2538956A4 (de) * | 2010-02-22 | 2015-04-22 | Edge Therapeutics Inc | Verfahren und zusammensetzungen zur behandlung hämorrhagischer zustände des gehirns |
| BR112016014617A2 (pt) * | 2014-01-24 | 2017-09-19 | Pfizer | Variante do fator xa (fxa) e usos da referida variante |
| EP3833381B1 (de) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7907398A (en) * | 1997-06-23 | 1999-01-04 | Novo Nordisk A/S | Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function |
| US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| EP1216709A1 (de) * | 2000-12-21 | 2002-06-26 | Boehringer Ingelheim Pharma KG | Verwendung von aktiviertem Gerinnungsfaktor VII zur Behandlung von durch thrombolytische Therapie-induzierten wichtigen Blutungen |
| BR0207007A (pt) * | 2001-02-05 | 2004-02-17 | Novo Nordisk Healthcare Ag | Composição farmcêutica, kit, usos de uma preparação e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia em um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em paciente e para intensificar a formação de coágulo de fibrina em um paciente |
| US20090156481A1 (en) * | 2005-07-15 | 2009-06-18 | Novo Nordisk Healthcare A/G | Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy |
-
2005
- 2005-06-21 WO PCT/EP2005/052890 patent/WO2005123118A1/en not_active Ceased
- 2005-06-21 ES ES05756838T patent/ES2331653T3/es not_active Expired - Lifetime
- 2005-06-21 RU RU2006144397/14A patent/RU2006144397A/ru not_active Application Discontinuation
- 2005-06-21 AT AT05756838T patent/ATE441430T1/de not_active IP Right Cessation
- 2005-06-21 KR KR1020077001163A patent/KR20070027709A/ko not_active Withdrawn
- 2005-06-21 AU AU2005253749A patent/AU2005253749A1/en not_active Abandoned
- 2005-06-21 EP EP05756838A patent/EP1761274B1/de not_active Expired - Lifetime
- 2005-06-21 JP JP2007517290A patent/JP5523671B2/ja not_active Expired - Fee Related
- 2005-06-21 DE DE602005016406T patent/DE602005016406D1/de not_active Expired - Lifetime
- 2005-06-21 CA CA002570330A patent/CA2570330A1/en not_active Abandoned
- 2005-06-21 BR BRPI0512316-0A patent/BRPI0512316A/pt not_active IP Right Cessation
- 2005-06-21 MX MXPA06015045A patent/MXPA06015045A/es not_active Application Discontinuation
- 2005-06-29 US US11/169,933 patent/US20060019894A1/en not_active Abandoned
-
2007
- 2007-03-27 US US11/728,940 patent/US20070243183A1/en not_active Abandoned
-
2012
- 2012-05-10 JP JP2012108693A patent/JP2012197279A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20060019894A1 (en) | 2006-01-26 |
| MXPA06015045A (es) | 2007-03-21 |
| WO2005123118A1 (en) | 2005-12-29 |
| BRPI0512316A (pt) | 2008-02-26 |
| CA2570330A1 (en) | 2005-12-29 |
| AU2005253749A1 (en) | 2005-12-29 |
| JP2008503543A (ja) | 2008-02-07 |
| ES2331653T3 (es) | 2010-01-12 |
| RU2006144397A (ru) | 2008-07-27 |
| DE602005016406D1 (de) | 2009-10-15 |
| KR20070027709A (ko) | 2007-03-09 |
| EP1761274A1 (de) | 2007-03-14 |
| US20070243183A1 (en) | 2007-10-18 |
| JP2012197279A (ja) | 2012-10-18 |
| JP5523671B2 (ja) | 2014-06-18 |
| EP1761274B1 (de) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551063T1 (de) | Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen | |
| IL192181A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
| UA98125C2 (ru) | Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний | |
| MY137828A (en) | Keratinocytes which may be used as a biologically active substances for the treatment of wounds | |
| DE602005018763D1 (de) | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität | |
| SE0200312D0 (sv) | Novel composition | |
| IL192103A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression | |
| WO2009079451A3 (en) | Compositions and methods of promoting wound healing | |
| TW200716145A (en) | Use of LGG in the manufacture of a medicament for the prevention or treatment of respiratory allergies | |
| ATE447948T1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen | |
| WO2005107872A3 (en) | Treating respiratory diseases with gycopyrrolate and analogues | |
| DE602005026276D1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
| DE60115054D1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
| MXPA05001885A (es) | El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica. | |
| ATE441430T1 (de) | Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich) | |
| DE60220512D1 (de) | Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit | |
| ATE444754T1 (de) | Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| TW200724146A (en) | Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant | |
| ATE431741T1 (de) | Marrubin und zusammensetzung zur verringerung von schnarchen, verpackung und verfahren | |
| WO2006076014A3 (en) | Interferon-alpha constructs for use in the treatment of sars | |
| WO2007009895A3 (en) | USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY | |
| PL375354A1 (en) | Use of treosulfan and derivatives thereof for treating multiple sclerosis | |
| MX2008011312A (es) | Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos. | |
| EA200601853A1 (ru) | Лечение нарушенной дыхательной функции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |